ETF profile for ProShares Ultra Nasdaq Biotechnology (BIB) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
BIB ETF Profile
| Family: |
ProShares |
| Name: |
ProShares Ultra Nasdaq Biotechnology |
|
|
| Inception Date: |
7-Apr-2010 |
| Termination Date: |
|
| Investment Objective: |
ProShares Ultra Nasdaq Biotechnology seeks daily investment results before fees and expenses that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology Index. |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| Derivatives offset |
|
-137.4922% |
| NASDAQ Biotechnology Index SWAP Bank of America NA |
|
31.7396% |
| NASDAQ Biotechnology Index SWAP Citibank NA |
|
31.7090% |
| NASDAQ Bio Index SWAP BNP Paribas |
|
29.8194% |
| NASDAQ Biotechnology Index SWAP Goldman Sachs International |
|
20.1882% |
| NASDAQ Biotechnology Index SWAP Societe Generale |
|
19.2243% |
| PROSHARES GENIUS MNY MKT ETF |
IQMM |
18.9115% |
| Net Other Assets (Liabilities) |
|
18.0769% |
| GILEAD SCIENCES INC |
GILD |
5.4538% |
| AMGEN INC |
AMGN |
5.1540% |
|
Top 10 Holdings Weight: |
42.8% |
| Number of Holdings: |
257 |
| Shares Outstanding: |
840,000 |
| Total Net Assets: |
89,951,568 |
| NAV: |
107.16 |
| Net Expense Ratio: |
0.95% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
US |
| Region: |
|
| Strategy: |
|
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Broad Market / Multi-Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
Leveraged (2x) |
| Is Currency Hedged: |
No |
| US or Ex-US: |
Domestic |
